FDA warns ketaminetroches.com that it sells unapproved and misbranded ketamine troches to U.S. consumers online.
What happened
FDA reviewed the website www.ketaminetroches.com on February 25, 2026, rather than conducting an inspection. FDA found the site offering "Ketamine Troches" with claims that they treat anxiety and depression, making the product a drug intended for human use. FDA says there is no approved application for this product and its labeling lacks adequate directions for use.
What FDA found
The company sells ketamine troches without an FDA-approved drug application, which the law requires for new drugs.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))Website claims that the troches treat anxiety and depression show the product is a drug intended for human use.
FD&C Act section 201(g) (21 U.S.C. 321(g)); 21 CFR 201.128The product's labeling does not give adequate directions for use, so it is misbranded.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The product is a prescription drug that cannot be used safely without a licensed practitioner's supervision, so a layperson cannot be given adequate directions.
FD&C Act section 503(b)(1) (21 U.S.C. 353(b)(1)); 21 CFR 201.5Because the drug is not approved in the United States, it does not qualify for the exemption from adequate-directions labeling.
21 CFR 201.115(a)Offering the product for sale to U.S. consumers puts a misbranded drug into interstate commerce.
FD&C Act section 301(a) (21 U.S.C. 331(a))
What FDA wants
FDA tells the company to stop offering unapproved and misbranded drugs for sale to U.S. consumers and to send a written response with corrective steps and supporting documents to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov, citing reference number MARCS-CMS 725148.
Who should pay attention
- compounding pharmacies that make or ship ketamine troches
- telehealth and online sellers of ketamine or psychedelic-adjacent products
- clinics and brands marketing unapproved drugs directly to patients
This is a summary. Read the original letter on fda.gov.